Intended preoperative trans-arterial embolization for large hepatocellular carcinoma: a retrospective cohort study

被引:6
作者
Saito, Ryo [1 ]
Amemiya, Hidetake [1 ]
Hosomura, Naohiro [1 ]
Kawaida, Hiromichi [1 ]
Shoda, Katsutoshi [1 ]
Furuya, Shinji [1 ]
Akaike, Hidenori [1 ]
Kawaguchi, Yoshihiko [1 ]
Inoue, Shingo [1 ]
Kono, Hiroshi [1 ]
Ichikawa, Daisuke [1 ]
机构
[1] Univ Yamanashi, Fac Med, Dept Surg 1, 1110 Shimokato, Chuo, Yamanashi 4093898, Japan
关键词
Trans-arterial embolization; Hepatectomy; Hepatocellular carcinoma; Large tumor; CHEMOEMBOLIZATION; HEPATECTOMY; PROGNOSIS; SURVIVAL;
D O I
10.1186/s12957-022-02563-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Generally, a large tumor size of hepatocellular carcinoma (HCC) is associated with poor visibility and uncertainty in the surgical field which results in increased surgical difficulty as well as unfavorable postoperative outcomes. We performed intended preoperative trans-arterial embolization (TAE) in patients with a large HCC. In this study, we investigated the oncological significance of intended preoperative TAE for a large HCC, using a comparison between patients with and without TAE, and detailed analyses for pre- and post-TAE status. Methods A total of 411 patients who underwent hepatectomy for primary HCC at the University of Yamanashi Hospital between January 2007 and December 2018 were included in this study. The patients were divided into two groups: patients with larger HCCs (>= 50 mm, n=51) and those with smaller HCC (<50 mm, n=360) according to the size of their HCCs. Comparison of clinicopathological features between these groups and clinical outcomes between the TAE and non-TAE groups were compared. In addition, a detailed analysis of each case in the TAE group was conducted, comparing clinicopathological factors between pre- and post-TAE status. Results The clinical unfavorable short- and long-term outcomes of patients with large HCCs (>= 50 mm) were revealed compared to those with small HCCs (<50 mm). The prognostic analyses showed that a large tumor size and increased tumor markers, multiple tumor numbers, and others were adverse prognostic factors, and vascular invasions and residual tumors were included in the multivariate analysis. Further detailed analyses revealed that the average rates of change in tumor size and tumor shrinkage after TAE were - 48.6 +/- 35.6 mm and - 30.7 +/- 17.0%, respectively. Pathological high necrotic changes in the tumor, after multiple-times TAE aiming to a better effect, were related to a better prognosis in patients with large HCC. Poor prognostic factors became less common in patients who underwent intended preoperative TAE, and these patients had better prognoses. Conclusions The large tumor size of HCC is associated with unfavorable outcomes; the intended preoperative TAE for large HCC patients performed multiple times aiming to affect the tumor as much as possible might improve their prognoses.
引用
收藏
页数:9
相关论文
共 28 条
[1]   World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects [J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20) :2191-2194
[2]   The efficacy of surgery in advanced hepatocellular carcinoma: a cohort study [J].
Chen, Lei ;
Sun, Tao ;
Chen, Shi ;
Ren, Yanqiao ;
Yang, Fan ;
Zheng, Chuansheng .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[3]   The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis [J].
Cheng, Zhoujing ;
He, Lin ;
Guo, Yingjie ;
Song, Yuhua ;
Song, Shasha ;
Zhang, Lijiu .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[4]   Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits [J].
Heinrich, Stefan ;
Lang, Hauke .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (08)
[5]   A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection [J].
Huang, Shenglan ;
Li, Dan ;
Zhuang, LingLing ;
Sun, Liying ;
Wu, Jianbing .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
[6]   Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis [J].
Jiang, Chuang ;
Cheng, Gong ;
Liao, Mingheng ;
Huang, Jiwei .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
[7]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458
[8]  
Kitagawa Y, 2019, ESOPHAGUS-TOKYO, V16, P25, DOI 10.1007/s10388-018-0642-8
[9]  
Kokudo Norihiro, 2019, Glob Health Med, V1, P23, DOI [10.35772/ghm.019.01018, 10.35772/ghm.2019.01018]
[10]   Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JS']JSH-HCC guidelines) 2019 update [J].
Kokudo, Norihiro ;
Takemura, Nobuyuki ;
Hasegawa, Kiyoshi ;
Takayama, Tadatoshi ;
Kubo, Shoji ;
Shimada, Mitsuo ;
Nagano, Hiroaki ;
Hatano, Etsuro ;
Izumi, Namiki ;
Kaneko, Shuichi ;
Kudo, Masatoshi ;
Iijima, Hiroko ;
Genda, Takuya ;
Tateishi, Ryosuke ;
Torimura, Takuji ;
Igaki, Hiroshi ;
Kobayashi, Satoshi ;
Sakurai, Hideyuki ;
Murakami, Takamichi ;
Watadani, Takeyuki ;
Matsuyama, Yutaka .
HEPATOLOGY RESEARCH, 2019, 49 (10) :1109-1113